首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >Crosslinking of saphenous vein ECM by procyanidins for small diameter blood vessel replacement
【24h】

Crosslinking of saphenous vein ECM by procyanidins for small diameter blood vessel replacement

机译:基因尼沙氨酸对小直径血管置换的杂交静脉ECM交联

获取原文
获取原文并翻译 | 示例
           

摘要

Xenogenic decellularized vessels, mainly composed of extracellular matrices (ECMs), are thought to be one of the alternative resources of small-diameter blood vessels due to abundant source, tubular configuration, vascular microstructure, and good cytocompatibility. However, the main shortcomings of ECM vessels are their low chemical stability, easy calcification, immunogenicity, and high risk of thrombogenicity. Previous studies have shown that, glutaraldehyde (GA), as a crosslinking agent, led to significant calcification and cytotoxicity for the prepared ECM substitutes. To overcome the drawbacks of pure and GA-crosslinked vascular alternatives of small-diameter blood vessels, procyanidins (PC), a naturally derived polyphenol with anti-inflammatory and platelet aggregation inhibiting bioactivities, was applied to crosslink the decellularized bovine saphenous vein ECM (svECM). After crosslinking, the obtained svECM substitutes exhibited natural tubular configuration with significantly improved mechanical properties, proper resistance to proteolysis, high chemical stability, and excellent anticalcification property. The PC-crosslinked svECM substitutes were cytocompatible for cells adhesion and proliferation, and blood compatible for erythrocytes with far less hemolysis than that of safety standard. Furthermore, the PC-crosslinked svECM substitutes showed distinct antithrombosis and anti-immunogenicity potential. With these advantages, it is suggested that the PC-crosslinked svECM may be used as a practical substitutes of small diameter blood vessels.
机译:致异叶脱细胞血管,主要由细胞外基质(ECM)组成,被认为是由于源极,管状配置,血管微观结构和良好的细胞组合,因此是小直径血管的替代资源之一。然而,ECM血管的主要缺点是它们的化学稳定性低,易钙化,免疫原性和血栓形成性高风险。以前的研究表明,作为交联剂的戊二醛(GA)导致制备的ECM替代物的显着钙化和细胞毒性。为了克服小直径血管的纯和GA交联的血管替代品的缺点,应用了一种具有抗炎和血小板聚集的天然衍生的多酚抑制生物活性,以交联脱细胞牛静脉静脉ECM(SVECM )。交联后,所获得的SVECM替代品具有显着提高的机械性能,对蛋白水解,高化学稳定性和优异的抗诊断性能的显着提高。 PC交联的SVECM替代物是细胞粘合的细胞粘附和增殖,并且对红细胞相容的血液与安全标准的溶血相容。此外,PC交联的SVECM替代物显示出明显的抗血栓形成和抗免疫原性潜力。通过这些优点,建议PC交联的SVECM可以用作小直径血管的实际替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号